Business Wire

THALES

12.6.2019 07:02:08 CEST | Business Wire | Press release

Share
Gemalto Identity Management System to Empower the World’s Citizens with Secure and Unique Identities

Gemalto, a Thales company, is launching its Identity Management System (IDMS) that can help governments address the challenges posed by a world in which over one billion people have no official ID. Using the latest biometric capture and identity verification techniques, Gemalto’s solutions enable public authorities to empower citizens with a fully secured and trusted Foundational Identity. This system supports people identification and authentication so they can securely access online and offline services such as education or healthcare, and proves their right to participate in elections, apply for a passport or open a bank account. Users retain full control over their personal data, choosing how and when it is shared with service providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005462/en/

UN targets universal provision of ID by 2030

The staggering number of citizens rendered invisible to public agencies by the absence of an official ID includes one out of three children worldwide. Most international financial institutions are supporting Digital ID schemes in many countries over the next ten years. These initiatives are also backed by the UN, which has itself set the target of everyone on the planet having a legal identity by 20301 .

Mobile, biometric-based registration can reach remote and isolated areas

Gemalto’s IDMS provides authorities with a fully integrated, end-to-end solution which can adapt to existing identity schemes and orchestrate its interactions. The process starts with registration of a person and capture of their biometrics, with easy-to use mobile technology ensuring coverage can reach even the most remote regions. Registration is followed by entry onto a central database or civil registry and the creation of a unique individual identifier.

Reaping the benefits of Foundational ID

This Foundational Identity can provide the basis for issuance of digital and physical ID credentials, and subsequent registration with numerous different public bodies and services. All these processes can be verified beyond doubt using the individual’s biometrics and unique identifier. Gemalto’s approach also offers citizens outstanding protection, and assurance that their data will not be used for commercial gain.

Promoting inclusion, fighting fraud

For governments, a universal ID program facilitates accurate planning of public services, and comprehensive social inclusion strategies. Robust protection against the threat of fraud is also provided, as part of the digital ID platform to further boost efficiency, convenience and adoption of eServices. The Foundational Identity also eliminates the need for individual bodies, such as those responsible for health and welfare, to continually repeat enrollment procedures.

“A unique legal ID is a basic human right that can unlock access to many more – including education, welfare and participation in the democratic process,” said Frédéric Trojani, senior vice president Identity and Biometric Solutions for Thales . “Our Identity Management System leverages unrivalled experience in delivering Digital Identity solutions that empower citizens, defend their personal data, and ensure unhindered access to the rights and services.”

Note to editors

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. Gemalto’s technologies and services authenticate people, transactions and objects, encrypt data and create value for software – enabling businesses and governments to deliver secure digital services for billions of individuals and things.

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.

PLEASE VISIT

Thales Group
Digital Security
Download HD photos

1 UN Sustainable Development Goal (SDG) 16.9

Contact:

PRESS Thales, Media Relations Security Constance Arnoux +33 (0)6 44 12 16 35 constance.arnoux@thalesgroup.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye